[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:papillary-renal-cell-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":43,"states":44},"Papillary Renal Cell Carcinoma",5,4,[8,16,22,29,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05287945","Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:30.145302Z","2026-05-05T02:43:29.048386Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05665361","Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)",[12],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:28.471273Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT04981509","Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer",[26],"Phase 2","2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.854522Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05433142","Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma",[33],"Phase 1","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:27.325189Z",{"nct_id":37,"title":38,"phases":39,"status":40,"updated_at":41,"content_modified":42},"NCT07243067","Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer",[],"NOT_YET_RECRUITING","2026-08-26T02:17:01.714035Z","2026-05-13T02:55:06.680960Z",[],[45],{"state":46,"count":47,"slug":48},"California",3,"california"]